CardiologyOnline.net

Cardiology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Dronedarone in the treatment of atrial fibrillation / atrial flutter in the aftermath of PALLAS


Dronedarone ( Multaq ) is an Amiodarone analog that differs structurally from Amiodarone in that the iodine moiety was removed and a methane-sulfonyl group was added.
These modifications reduce thyroid and other end-organ adverse effects and makes Dronedarone less lipophilic, with a shorter half-life.

Dronedarone has been shown to prevent atrial fibrillation/ flutter ( AF/AFl ) recurrences in several multi-center trials.

In addition to its rhythm control properties, Dronedarone has rate control properties.

In patients with decompensated heart failure, Dronedarone treatment increased mortality and cardiovascular hospitalizations.

When Dronedarone was used in elderly high risk AF/AFl patients, excluding those with advanced heart failure, cardiovascular hospitalizations were significantly reduced.

The results of the PALLAS trial suggest that Dronedarone should not be used in the long-term treatment of patients with permanent atrial fibrillation.

Post-marketing data have demonstrated rare hepatic toxicity to be associated with Dronedarone use.

Updated practice and regulatory guidelines have positioned Dronedarone as a front-line antiarrhythmic in many patients with atrial fibrillation / atrial flutter.
However, the drug should not be used in patients with advanced heart failure and in patients who develop permanent atrial fibrillation. ( Xagena )

Naccarelli GV, Kowey PR, Curr Cardiol Rev 2014;10:303-308

XagenaMedicine_2014



Indietro